Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Atelectasis II: Pathophysiology

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Vaccine-related environments and patient preferences in Japanese patients with autoimmune rheumatic diseases.

Modern rheumatology·2025

Same author

Successful treatment of lupus protein-losing enteropathy with belimumab: A case report.

Modern rheumatology case reports·2024

Same author

2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease.

Respiratory investigation·2021

Same author

Concurrent onset of acute lupus myocarditis, pulmonary arterial hypertension and digital gangrene in a lupus patient: a possible role of vasculitis to the rare disorders.

Modern rheumatology case reports·2020

Same author

Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.

Current medical research and opinion·2020

Same author

JCS 2017 Guideline on Management of Vasculitis Syndrome　- Digest Version.

Circulation journal : official journal of the Japanese Circulation Society·2020

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

ANCA: associated lung fibrosis.

Hidehiro Yamada¹

¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Miyamaeku, Kawasaki, Japan.

Seminars in Respiratory and Critical Care Medicine

|June 16, 2011

Summary

Pulmonary fibrosis (PF) may be an underestimated sign of ANCA-associated vasculitis. Early ANCA testing in PF patients is crucial for identifying those at risk of vasculitis and ensuring timely monitoring.

Area of Science:

Rheumatology
Pulmonology
Immunology

Background:

The relationship between pulmonary fibrosis (PF), anti-neutrophil cytoplasmic autoantibody (ANCA) positivity, and vasculitis is not well-defined.
Recent studies suggest PF is an underrecognized manifestation of ANCA-associated vasculitis.

Purpose of the Study:

To review the literature on the link between pulmonary fibrosis and ANCA-associated vasculitis.
To highlight clinical characteristics, diagnostic findings, and prognostic implications.

Main Methods:

Retrospective analysis of five case-control studies published over the past six years.
Review of clinical characteristics, laboratory findings, and imaging results.

Main Results:

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Related Experiment Videos

Last Updated: Jun 1, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Pulmonary fibrosis is an underestimated manifestation of ANCA-associated vasculitis.

Common features include older age, myeloperoxidase (MPO)-ANCA positivity, and poor prognosis.

PF diagnosis often precedes vasculitis onset.

No significant differences in pulmonary function, bronchoalveolar lavage, or HRCT findings between ANCA-associated PF and idiopathic pulmonary fibrosis (IPF).

Conclusions:

The high mortality of ANCA-associated PF necessitates ANCA screening in all PF patients.
Positive MPO-ANCA indicates increased vasculitis risk and warrants specific patient monitoring.